Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma

NCT05464329 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Large B-cell Lymphoma
High-grade B-cell Lymphoma
Transformed B-Cell Lymphoma
Follicular Lymphoma Grade 3B

Interventions

DRUG: Mosunetuzumab
DRUG: DHAX
DRUG: ICE

Sponsor

Washington University School of Medicine

Collaborators

Genentech, Inc.